Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Quest Partners LLC

Quest Partners LLC decreased its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 86.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 632 shares of the company’s stock after selling 4,177 shares during the quarter. Quest Partners LLC’s holdings in Keros Therapeutics were worth $37,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. KBC Group NV grew its position in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics during the third quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Keros Therapeutics in the second quarter valued at about $128,000. Finally, Victory Capital Management Inc. purchased a new position in shares of Keros Therapeutics in the third quarter worth about $216,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

Shares of KROS stock opened at $57.74 on Monday. Keros Therapeutics, Inc. has a 1 year low of $27.31 and a 1 year high of $73.00. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -11.08 and a beta of 1.23. The stock’s 50-day moving average is $59.49 and its two-hundred day moving average is $52.28.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm’s revenue was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.33) earnings per share. As a group, research analysts predict that Keros Therapeutics, Inc. will post -5.28 EPS for the current year.

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of analyst reports. Scotiabank assumed coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target for the company. Guggenheim assumed coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective on the stock. Jefferies Financial Group began coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating on the stock. Wedbush reissued an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, Bank of America cut their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, Keros Therapeutics currently has an average rating of “Buy” and a consensus price target of $88.89.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.